Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm by Ghayas C. Issa, Courtney D. DiNardo

Get full text

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia by Aram Bidikian, Hagop Kantarjian, Elias Jabbour, Nicholas J. Short, Keyur Patel, Farhad Ravandi, Koji Sasaki, Ghayas C. Issa

Get full text

Management of chronic myeloid leukemia in 2023 – common ground and common sense by Jayastu Senapati, Koji Sasaki, Ghayas C. Issa, Jeffrey H. Lipton, Jerald P. Radich, Elias Jabbour, Hagop M. Kantarjian

Get full text

Nontuberculosis mycobacteria (NTM) infections in patients with leukemia: a single center case series by Jennifer Marvin-Peek, Koji Sasaki, Dimitrios P. Kontoyiannis, Javier Adachi, Maro Ohanian, Koichi Takahashi, Ghayas C. Issa, Steven Kornblau, Hussein A. Abbas, Hussein A. Abbas

Get full text

Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia by Iman Abou Dalle, Ronald Paranal, Jabra Zarka, Shilpa Paul, Koji Sasaki, Wen Li, Jing Ning, Nicholas J. Short, Maro Ohanian, Jorge E. Cortes, Elias J. Jabbour, Ghayas C. Issa

Get full text

Calibration-free NGS quantitation of mutations below 0.01% VAF by Peng Dai, Lucia Ruojia Wu, Sherry Xi Chen, Michael Xiangjiang Wang, Lauren Yuxuan Cheng, Jinny Xuemeng Zhang, Pengying Hao, Weijie Yao, Jabra Zarka, Ghayas C. Issa, Lawrence Kwong, David Yu Zhang

Get full text

Myeloid lineage switch in <i>KMT2A-</i>rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies by Alex Bataller, Tareq Abuasab, David McCall, Wei Wang, Branko Cuglievan, Ghayas C. Issa, Elias Jabbour, Nicholas Short, Courtney D. DiNardo, Guilin Tang, Guillermo Garcia-Manero, Hagop M. Kantarjian, Koji Sasaki

Get full text

P561: REVUMENIB IN PATIENTS WITH ACUTE LEUKEMIAS: COMPASSIONATE USE PROGRAM EXPERIENCE by Jeffrey Rubnitz, Ghayas C. Issa, Eytan M. Stein, Neerav Shukla, Wendy Stock, Andrius Žučenka, Sajad Khazal, Nandita Khera, Elliot Stieglitz, Jeremy Rubinstein, Galit Rosen, Rachel Ghiraldi, Huy Van Nguyen, Nicole Mcneer, C. Michel Zwaan

Get full text

Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series by Ahmad S. Alotaibi, Musa Yilmaz, Sanam Loghavi, Courtney DiNardo, Gautam Borthakur, Tapan M. Kadia, Beenu Thakral, Naveen Pemmaraju, Ghayas C. Issa, Marina Konopleva, Nicholas J. Short, Keyur Patel, Guilin Tang, Farhad Ravandi, Naval Daver

Get full text

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience by Kamal Chamoun, Hagop Kantarjian, Rami Atallah, Graciela Nogueras Gonzalez, Ghayas C. Issa, Mary Beth Rios, Guillermo Garcia-Manero, Gautam Borthakur, Farhad Ravandi, Nitin Jain, Naval Daver, Marina Konopleva, Courtney D. DiNardo, Tapan Kadia, Naveen Pemmaraju, Elias Jabbour, Jorge Cortes

Get full text

Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy by Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Sa A. Wang, Wei Wang, Sanam Loghavi, Naval G. Daver, Courtney D. DiNardo, Ghayas C. Issa, Hussein A. Abbas, Cedric Nasnas, Alex Bataller, Samuel Urrutia, Omer S. Karrar, Sherry Pierce, Hagop M. Kantarjian, Nicholas J. Short

Get full text

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements by Ghayas C. Issa, Jabra Zarka, Koji Sasaki, Wei Qiao, Daewoo Pak, Jing Ning, Nicholas J. Short, Fadi Haddad, Zhenya Tang, Keyur P. Patel, Branko Cuglievan, Naval Daver, Courtney D. DiNardo, Elias Jabbour, Tapan Kadia, Gautam Borthakur, Guillermo Garcia-Manero, Marina Konopleva, Michael Andreeff, Hagop M. Kantarjian, Farhad Ravandi

Get full text

Outcomes and genetic dynamics of acute myeloid leukemia at first relapse by Alex Bataller, Hagop Kantarjian, Alexandre Bazinet, Tapan Kadia, Naval Daver, Courtney D. DiNardo, Gautam Borthakur, Sanam Loghavi, Keyur Patel, Guilin Tang, Koji Sasaki, Nicholas J. Short, Musa Yilmaz, Ghayas C. Issa, Yesid Alvarado, Guillermo Montalban-Bravo, Abhishek Maiti, Hussein A. Abbas, Koichi Takahashi, Sherry Pierce, Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi

Get full text

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure by Nicholas J. Short, Sangeetha Venugopal, Wei Qiao, Tapan M. Kadia, Farhad Ravandi, Walid Macaron, Courtney D. Dinardo, Naval Daver, Marina Konopleva, Gautam Borthakur, Elizabeth J. Shpall, Uday Popat, Richard E. Champlin, Rohtesh Mehta, Gheath Al-Atrash, Betul Oran, Elias Jabbour, Guillermo Garcia-Manero, Ghayas C. Issa, Guillermo Montalban-Bravo, Musa Yilmaz, Abhishek Maiti, Hagop Kantarjian

Get full text

A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative an... by Jayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, Hussein A. Abbas, Sanam Loghavi, Gautam Borthakur, Musa Yilmaz, Ghayas C. Issa, Samuel I. Dara, Mahesh Basyal, Li Li, Kiran Naqvi, Rasoul Pourebrahim, Elias J. Jabbour, Steven M. Kornblau, Nicholas J. Short, Naveen Pemmaraju, Guillermo Garcia-Manero, Farhad Ravandi, Joseph Khoury, Naval Daver, Hagop M. Kantarjian, Michael Andreeff, Courtney D. DiNardo

Get full text

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia by Abhishek Maiti, Courtney D. DiNardo, Naval G. Daver, Caitlin R. Rausch, Farhad Ravandi, Tapan M. Kadia, Naveen Pemmaraju, Gautam Borthakur, Prithviraj Bose, Ghayas C. Issa, Nicholas J. Short, Musa Yilmaz, Guillermo Montalban-Bravo, Alessandra Ferrajoli, Elias J. Jabbour, Nitin Jain, Maro Ohanian, Koichi Takahashi, Philip A. Thompson, Sanam Loghavi, Kathryn S. Montalbano, Sherry Pierce, William G. Wierda, Hagop M. Kantarjian, Marina Y. Konopleva

Get full text

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents by Nicholas J. Short, Muharrem Muftuoglu, Faustine Ong, Lewis Nasr, Walid Macaron, Guillermo Montalban-Bravo, Yesid Alvarado, Mahesh Basyal, Naval Daver, Courtney D. Dinardo, Gautam Borthakur, Nitin Jain, Maro Ohanian, Elias Jabbour, Ghayas C. Issa, Wei Qiao, Xuelin Huang, Rashmi Kanagal-Shamanna, Keyur P. Patel, Prithviraj Bose, Farhad Ravandi, Ricardo Delumpa, Regina Abramova, Guillermo Garcia-Manero, Michael Andreeff, Jorge Cortes, Hagop Kantarjian

Get full text

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents by Danielle Hammond, Sanam Loghavi, Sa A. Wang, Marina Y. Konopleva, Tapan M. Kadia, Naval G. Daver, Maro Ohanian, Ghayas C. Issa, Yesid Alvarado, Nicholas J. Short, Koji Sasaki, Naveen Pemmaraju, Guillermo Montalban-Bravo, Curtis A. Lachowiez, Abhishek Maiti, Guillermo Garcia-Manero, Elias J. Jabbour, Gautam Borthakur, Farhad Ravandi, Koichi Takahashi, Sherry R. Pierce, Hagop M. Kantarjian, Courtney D. DiNardo

Get full text

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens by Abhishek Maiti, Caitlin R. Rausch, Jorge E. Cortes, Naveen Pemmaraju, Naval G. Daver, Farhad Ravandi, Guillermo Garcia-Manero, Gautam Borthakur, Kiran Naqvi, Maro Ohanian, Nicholas J. Short, Yesid Alvarado, Tapan M. Kadia, Koichi Takahashi, Musa Yilmaz, Nitin Jain, Steven Kornblau, Guillermo Montalban Bravo, Koji Sasaki, Michael Andreeff, Prithiviraj Bose, Alessandra Ferrajoli, Ghayas C. Issa, Elias J. Jabbour, Lucia Masarova, Philip A. Thompson, Sa Wang, Sergej Konoplev, Sherry A. Pierce, Jing Ning, Wei Qiao, John S. Welch, Hagop M. Kantarjian, Courtney D. DiNardo, Marina Y. Konopleva

Get full text